UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors

Molecular cancer therapeutics, 2020-10, Vol.19 (10), p.2155-2162

2020

Volltextzugriff (PDF)

Phase 1 study of EUS-guided photodynamic therapy for locally advanced pancreatic cancer

Gastrointestinal endoscopy, 2019-02, Vol.89 (2), p.390-398

2019

Volltextzugriff (PDF)

A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review

The American journal of gastroenterology, 2017-04, Vol.112 (4), p.537-554

2017

Volltextzugriff (PDF)

Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin

Journal of cachexia, sarcopenia and muscle, 2022-08, Vol.13 (4), p.2146-2161

2022

Volltextzugriff (PDF)

Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer

Journal of cachexia, sarcopenia and muscle, 2018-08, Vol.9 (4), p.673-684

2018

Volltextzugriff (PDF)

The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy

Journal of cachexia, sarcopenia and muscle, 2019-10, Vol.10 (5), p.1083-1101

2019

Volltextzugriff (PDF)

Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma

American journal of clinical oncology, 2018-10, Vol.41 (10), p.982-985

2018

Volltextzugriff (PDF)

A systematic review of psychosocial interventions for colorectal cancer patients

Supportive care in cancer, 2017-07, Vol.25 (7), p.2349-2362

2017

Volltextzugriff (PDF)

Profiling of Adipose and Skeletal Muscle in Human Pancreatic Cancer Cachexia Reveals Distinct Gene Profiles with Convergent Pathways

Cancers, 2021-04, Vol.13 (8), p.1975

2021

Volltextzugriff (PDF)

The human metapneumovirus: a case series and review of the literature

Transplant infectious disease, 2011-06, Vol.13 (3), p.324-328

2011

Volltextzugriff (PDF)

BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Blood, 2021-11, Vol.138 (Supplement 1), p.3742-3742

2021

Volltextzugriff (PDF)

Su1367 PHASE I STUDY OF EUS-GUIDED PHOTODYNAMIC THERAPY FOR LOCALLY ADVANCED PANCREATIC CANCER

Gastrointestinal endoscopy, 2018-06, Vol.87 (6), p.AB323-AB324

2018

Volltextzugriff (PDF)

Abstract B85: Pathologic complete response following systemic chemotherapy with or without chemoradiotherapy for borderline resectable/unresectable pancreatic adenocarcinoma: Indiana University experience

Cancer research (Chicago, Ill.), 2016-12, Vol.76 (24_Supplement), p.B85-B85

2016

Volltextzugriff (PDF)

Identification of Potential Serum Protein Biomarkers and Pathways for Pancreatic Cancer Cachexia Using an Aptamer-Based Discovery Platform

Cancers, 2020-12, Vol.12 (12), p.3787

2020

Volltextzugriff (PDF)

CLL-116 BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed-Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S267

2022

Volltextzugriff (PDF)

Poster: CLL-116 BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed-Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S145

2022

Volltextzugriff (PDF)

Neoadjuvant therapy duration and outcome of patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC)

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.436-436

2019

Volltextzugriff (PDF)

Survival after recurrence following curative intent resection of pancreatic adenocarcinoma

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e15760-e15760

2017

Volltextzugriff (PDF)

Abstract B89: Neoadjuvant FOLFIRINOX in patients with resectable pancreatic cancer

Cancer research (Chicago, Ill.), 2016-12, Vol.76 (24_Supplement), p.B89-B89

2016

Volltextzugriff (PDF)

Kinetics and dosimetric predictors of acute radiation-induced lymphopenia in pancreatic cancer

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.300-300

2018

Volltextzugriff (PDF)

Two Months of Therapy: A Case of Pathologic Complete Response to Chemoimmunotherapy in a Patient With Metastatic Colorectal Cancer

Clinical colorectal cancer, 2018-06, Vol.17 (2), p.e229-e232

2018

Volltextzugriff (PDF)

Abstract 1911: Analysis of the pancreatic cancer (PC) genome by immunohistochemistry (IHC) and comparative genome hybridization (CGH) in patients with long term survival with metastatic disease (mPC) treated on a phase II molecular profiling trial

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.1911-1911

2013

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(22)

Sprache

Englisch
(22)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(12)
Science & Technology
(12)
Humans
(8)
Oncology
(6)
Cachexia
(5)
Female
(5)
Pancreatic Cancer
(5)
Cancer Therapies
(4)
Male
(4)
Mortality
(4)
Aged
(3)
Carcinoma, Pancreatic Ductal - Complications
(3)
Care And Treatment
(3)
Chemotherapy
(3)
Gene Expression
(3)
General & Internal Medicine
(3)
Geriatrics & Gerontology
(3)
Health Aspects
(3)
Medicine, General & Internal
(3)
Middle Aged
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors

Phase 1 study of EUS-guided photodynamic therapy for locally advanced pancreatic cancer

A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review

Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin

Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer

The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy

Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma

A systematic review of psychosocial interventions for colorectal cancer patients

Profiling of Adipose and Skeletal Muscle in Human Pancreatic Cancer Cachexia Reveals Distinct Gene Profiles with Convergent Pathways

The human metapneumovirus: a case series and review of the literature

BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Su1367 PHASE I STUDY OF EUS-GUIDED PHOTODYNAMIC THERAPY FOR LOCALLY ADVANCED PANCREATIC CANCER

Abstract B85: Pathologic complete response following systemic chemotherapy with or without chemoradiotherapy for borderline resectable/unresectable pancreatic adenocarcinoma: Indiana University experience

Identification of Potential Serum Protein Biomarkers and Pathways for Pancreatic Cancer Cachexia Using an Aptamer-Based Discovery Platform

CLL-116 BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed-Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Poster: CLL-116 BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed-Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Neoadjuvant therapy duration and outcome of patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC)

Survival after recurrence following curative intent resection of pancreatic adenocarcinoma

Abstract B89: Neoadjuvant FOLFIRINOX in patients with resectable pancreatic cancer

Kinetics and dosimetric predictors of acute radiation-induced lymphopenia in pancreatic cancer

Two Months of Therapy: A Case of Pathologic Complete Response to Chemoimmunotherapy in a Patient With Metastatic Colorectal Cancer

Abstract 1911: Analysis of the pancreatic cancer (PC) genome by immunohistochemistry (IHC) and comparative genome hybridization (CGH) in patients with long term survival with metastatic disease (mPC) treated on a phase II molecular profiling trial

Suchergebnisse filtern